ClinicalTrials.gg
RecruitingNCT07029490EMPOWERUpdated Nov 21, 2025

Enhancing Mammography Programs for Outreach, Wellness, Education, and Resources (EMPOWER) in Underserved Populations Study

An interventional study of Chatbot in Breast Cancer, sponsored by University of Utah. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by University of Utah · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,700
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 33 studies in Breast Neoplasms by University of Utah — 9 open to participants now, 9 under way, 1 of them phase 3. Breast Neoplasms · University of Utah.

Planned enrollment
Largest of 33
2,700 · median 34
Started
2025
with 7 others
No phase
14 of 33
4 open now
Registered
27th of 33
by date

Among the 33 studies in Breast Neoplasms by University of Utah, this one has the largest planned enrollment, is one of 8 that started in 2025, is one of 14 with no phase, and was the 27th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 33 studies in Breast Neoplasms by University of Utah are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Breast Neoplasms by University of Utah, or all of them as a file.
02

Study summary

This study is investigating the feasibility of a digital tool called a chatbot for providing educational information about mammography through a tablet, computer, or phone. This study will recruit participants who recently had a mammogram with the University of Utah. Based on their mammography results, women will be placed into two cohorts using their BI-RADS category. Once mammogram results are available, patients will be randomized 1:1 to either usual care or usual care with chatbot. This study will randomly invite participants from four groups for focus group discussions (FGDs) based on their mammogram results and adherence to screening recommendations

Read the detailed description

Breast cancer screening inequities are drivers of disparities for rural and Latina women.

Chatbots are increasingly popular in various healthcare contexts and can be easily accessed through smartphones, tablets, laptops, and desktops. Chatbots have many advantages for patient messaging, including providing scripted education and motivational information interactively, chunking information into digestible segments, and allowing for choice in the amount of information received at any one time. Thus, with chatbots this study can tailor the interaction based on individual patient factors. Chatbots are accessible to the vast majority of U.S. adults. While chatbots have been used successfully in some clinical contexts, there is a lack of studies that investigated the use of chatbots as part of a mobile screening program to increase adherence to follow-up recommendations about either screening or diagnostic care.

Study staff will approach women at the time of or soon after a patient's routine breast cancer screening and invite the patient to participate in the study. Participants will complete baseline surveys at time of enrollment. This survey includes demographics and preferred contact method (e.g., text, email) that will be used to initiate the chatbot communication which can be completed via phone or website. Usual clinical procedures will be used to interpret participants' routine screening mammograms, including the use of the breast imaging-reporting and data system (BI-RADS), typically within 1 week of imaging.

Based on their mammography results, women will be placed into two cohorts using their BI-RADS category.

All participants will complete follow-up questionnaires, available in English and Spanish. For the follow-up surveys, the research team will contact participants via their preferred method (text or email) and send a link to the follow-up survey. If unsuccessful, the research team will then contact participants by phone to complete the survey via text or call.

Once mammogram results are available, patients will be randomized 1:1 to either usual care or usual care with chatbot, with randomization in permuted blocks of size and stratified by age (\<55 vs. ≥55 years, a proxy for menopause and indicator of risk); rural/frontier vs. urban; language preference (English vs. Spanish); and cohort (normal vs. abnormal result).

This study will randomly invite participants from four groups for focus group discussions (FGDs) based on their mammogram results and adherence to screening recommendations. This study aim to conduct 8 FGDs (2 per group, one in Spanish and one in English) with 8-10 participants each.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Mammography
  • Chatbot
  • Mobile Mammography
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (equal to or above 18 years old)
  • English or Spanish speaking
  • Visit a mammography program for routine screening.

Exclusion criteria

Exclusion Criteria:

  • Patients who are currently in treatment for breast cancer
  • Patients who are not of 18 years of age.
  • Patients who don't speak English or Spanish
  • Men
  • Cognitive limitations that impede
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,700 participants (estimated)

Study arms

  • No intervention
    Usual Care

    Usual Care: This will include participants randomized to usual care.

  • Experimental
    Chatbot

    Chatbot: This will include participants randomized to usual care with the Chatbot.

    Other: Chatbot

Interventions

  • OtherChatbot

    The Chatbot used in this study will be used after mammography to facilitate follow-up, answer patient questions, and provide information.

06

What researchers measure

Primary outcomes

  1. Screening Adherence

    This outcome measure will test the addition of virtual navigation to usual processes of care to increase screening adherence for underserved women undergoing mobile mammography who have an abnormal breast cancer screening exam. Screening adherence will be measured as a two-point survey item (Yes/No). This outcome measure will report the proportion of participants who self-reported screening adherence.

    Time frame: up to 24 months from initiation of study intervention

Secondary outcomes

  1. Receipt of follow-up testing

    This outcome measure will test the addition of virtual navigation to usual processes of care to increase follow-up testing for underserved women undergoing mobile mammography who have an abnormal breast cancer screening exam. Receipt of follow-up testing will be measured as survey items. For subjects who were recommended to have additional breast imaging or a breast biopsy, this will report if they completed the recommendation. This outcome measure will report the proportion of individuals who received all recommended follow-up tests after an initial breast screening indicating additional breast imaging or biopsy.

    Time frame: up to 12 months from initiation of study intervention

  2. Receipt of episode completion

    This outcome measure will test the addition of virtual navigation to usual processes of care to increase episode completion for underserved women undergoing mobile mammography who have an abnormal breast cancer screening exam. Receipt of episode completion will be measured through a survey. This outcome measure will report the proportion of subjects who complete all recommended follow-up steps after initial breast cancer screening or diagnosis, including imaging, biopsy, specialist appointments, and initiation of treatment if applicable.

    Time frame: up to 12 months from initiation of study intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Cancer Stat Facts: Female Breast Cancer. https://seer.cancer.gov/statfacts/html/breast.html. Accessed Oct 11, 2021.
  • American Cancer Society. Cancer Facts & Figures for Hispancis/Latinos 2018-2020. Atlanta: American Cancer Society, Inc.;2018.
  • Death Rates for Selected Cancers by Race and Ethnicity, US, 2010-2014. 2016; https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/death-rates-for-selected-cancers-by-race-and-ethnicity-us-2010-2014.pdf. Accessed Oct 11, 2021.
  • Henry KA, Sherman R, Farber S, Cockburn M, Goldberg DW, Stroup AM. The joint effects of census tract poverty and geographic access on late-stage breast cancer diagnosis in 10 US States. Health Place. 2013 May;21:110-21. doi: 10.1016/j.healthplace.2013.01.007. Epub 2013 Mar 1. PubMed 23454732 ↗
  • DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017 Nov;67(6):439-448. doi: 10.3322/caac.21412. Epub 2017 Oct 3. PubMed 28972651 ↗
  • Doescher MP, Jackson JE. Trends in cervical and breast cancer screening practices among women in rural and urban areas of the United States. J Public Health Manag Pract. 2009 May-Jun;15(3):200-9. doi: 10.1097/PHH.0b013e3181a117da. PubMed 19363399 ↗
  • Roche LM, Niu X, Stroup AM, Henry KA. Disparities in Female Breast Cancer Stage at Diagnosis in New Jersey: A Spatial-Temporal Analysis. J Public Health Manag Pract. 2017 Sep/Oct;23(5):477-486. doi: 10.1097/PHH.0000000000000524. PubMed 28430705 ↗
  • Williams F, Jeanetta S, O'Brien DJ, Fresen JL. Rural-urban difference in female breast cancer diagnosis in Missouri. Rural Remote Health. 2015 Jul-Sep;15(3):3063. Epub 2015 Jul 29. PubMed 26223824 ↗
  • Bennett KJ, Pumkam C, Bellinger JD, Probst JC. Cancer screening delivery in persistent poverty rural counties. J Prim Care Community Health. 2011 Oct 1;2(4):240-9. doi: 10.1177/2150131911406123. Epub 2011 May 17. PubMed 23804842 ↗
  • Bennett KJ, Probst JC, Bellinger JD. Receipt of cancer screening services: surprising results for some rural minorities. J Rural Health. 2012 Jan;28(1):63-72. doi: 10.1111/j.1748-0361.2011.00365.x. Epub 2011 Mar 11. PubMed 22236316 ↗
  • Coughlin SS, Leadbetter S, Richards T, Sabatino SA. Contextual analysis of breast and cervical cancer screening and factors associated with health care access among United States women, 2002. Soc Sci Med. 2008 Jan;66(2):260-75. doi: 10.1016/j.socscimed.2007.09.009. Epub 2007 Nov 19. PubMed 18022299 ↗
  • Horner-Johnson W, Dobbertin K, Iezzoni LI. Disparities in receipt of breast and cervical cancer screening for rural women age 18 to 64 with disabilities. Womens Health Issues. 2015 May-Jun;25(3):246-53. doi: 10.1016/j.whi.2015.02.004. Epub 2015 Apr 9. PubMed 25864023 ↗
  • Leung J, McKenzie S, Martin J, McLaughlin D. Effect of rurality on screening for breast cancer: a systematic review and meta-analysis comparing mammography. Rural Remote Health. 2014;14(2):2730. Epub 2014 Jun 23. PubMed 24953122 ↗
  • Incidence Rates for Utah by County Breast (Late Stage), 2014-2018, All Races (includes Hispanic), Female, All Ages. https://statecancerprofiles.cancer.gov/map/map.withimage.php?49&county&001&055211&00&2&11&0&1&5&0#results. Accessed Oct 11, 2021.
  • Guillaume E, Launay L, Dejardin O, Bouvier V, Guittet L, Dean P, Notari A, De Mil R, Launoy G. Could mobile mammography reduce social and geographic inequalities in breast cancer screening participation? Prev Med. 2017 Jul;100:84-88. doi: 10.1016/j.ypmed.2017.04.006. Epub 2017 Apr 10. PubMed 28408217 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Mar 2028, 28 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 28 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2025
First posted
Jun 19, 2025
StartActual
Nov 19, 2025
Primary completionEst.
Mar 2028
CompletionEst.
Sep 2028
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07029490
Lead sponsor
University of Utah
Collaborators
American Cancer Society, Inc.
Responsible party
Sponsor
First posted
Jun 19, 2025
Start date
Nov 19, 2025
Primary completion
Mar 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Nov 21, 2025

Study contacts

Anthony Ariotti
Contact
anthony.ariotti@hsc.utah.edu
801-213-6542

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion